Author

Silvio Danese

THE PHARMACOKINETICS AND IMMUNOGENICITY OF USTEKINUMAB AND ADALIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE SEAVUE STUDY
THE PHARMACOKINETICS AND IMMUNOGENICITY OF USTEKINUMAB AND ADALIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE SEAVUE STUDY

Silvio Danese  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN_S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN_S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN´S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN´S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL

Silvio Danese  et al.

EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY
LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY

Silvio Danese  et al.

RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES
LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES

OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Silvio Danese  et al.

EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Silvio Danese  et al.

ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB
ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB

Silvio Danese  et al.

SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS
SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS

Small molecules for Crohn's disease
Small molecules for Crohn's disease

Silvio Danese

Crohn's disease: A lymph draining dysfunction
Crohn's disease: A lymph draining dysfunction

Silvio Danese

EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

Silvio Danese  et al.

LONG-TERM TREATMENT WITH VEDOLIZUMAB SC IN ULCERATIVE COLITIS: INTERIM RESULTS FROM VISIBLE OLE
LONG-TERM TREATMENT WITH VEDOLIZUMAB SC IN ULCERATIVE COLITIS: INTERIM RESULTS FROM VISIBLE OLE

Silvio Danese  et al.

EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION
EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

Silvio Danese  et al.

ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: CHRONIC THERAPY DATA FROM THE VIBRATO UMBRELLA STUDY
ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: CHRONIC THERAPY DATA FROM THE VIBRATO UMBRELLA STUDY

Silvio Danese  et al.

TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL

Silvio Danese  et al.

NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE
NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE

Silvio Danese  et al.

Item 41 - 60 / 152
1 2
3
4 5 6 7 8